A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220672

Enrollment

280

Registered

2009-02-10

Start date

2009-02-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with type 2 diabetes

Interventions

investigational material(s) Generic name etc : OPC-262 INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : o

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Type 2 diabetes patients with HbA1c above 7.0% and below 10% - Patients who are capable of giving informed consent - Patients who are able to take contraceptive measures to avoid pregnancy of the patient or the patient's partner

Exclusion criteria

Exclusion criteria: - Patients with type1 diabetes mellitus, patients with diabetes mellitus or impaired glucose tolerance (IGT) due to other specified mechanism or diseases, and patients with gestational diabetes mellitus - Patients with a medical history of diabetes coma - Patients with poorly-controlled hypertension - Patients with heart failure - Patients with a complication of active hepatitis or hepatic cirrhosis - Patients undergoing treatment of glomeruler diseases other than diabetic nephropathy - Patients with a history or complication of malignant tumor

Design outcomes

Primary

Measure	Time frame
changes in HbA1C from baseline 2w, 4w, 8w, 12w	—

Secondary

Measure	Time frame
values changes in HbA1C from baseline 2w, 4w, 8w, 12w	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026